PMID- 24941379
OWN - NLM
STAT- MEDLINE
DCOM- 20140930
LR  - 20211021
IS  - 0893-9675 (Print)
IS  - 0893-9675 (Linking)
VI  - 19
IP  - 1-2
DP  - 2014
TI  - NK cells in therapy of cancer.
PG  - 133-41
AB  - Natural killer (NK) cells recognize targets stressed by malignant transformation 
      or infection and can be long-lived. They become educated by interacting with 
      major histocompatibility antigen (MHC) class I molecules to gain function to kill 
      targets and produce cytokines. In the clinic, haploidentical NK cells can be 
      adoptively transferred to treat cancer. Persistence and in vivo expansion of NK 
      cells depends on lymphodepleting chemotherapy to make space and induce release of 
      endogenous IL-15. In vivo expansion is also enhanced by cytokine administration 
      but IL-2 has the down side of stimulating CD25hi regulatory T cells (Tregs). 
      Other limitations to NK-cell therapy include poor in vivo survival and lack of 
      specificity. Bispecific or trispecific killer engagers that target CD16 on NK 
      cells to enhance recognition of tumor antigens, and desintegrin and 
      metalloproteinase 17 (ADAM17) inhibition that prevents CD16 shedding after 
      NK-cell activation should promote enhanced killing of cancer with specificity. 
      These are exciting times; more than 35 years after NK cells were initially 
      described, we are exploiting their capacity for clinical therapy.
FAU - Bachanova, Veronika
AU  - Bachanova V
AD  - Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN.
FAU - Miller, Jeffrey S
AU  - Miller JS
AD  - Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN.
LA  - eng
GR  - P01 CA65493/CA/NCI NIH HHS/United States
GR  - UL1TR000114/TR/NCATS NIH HHS/United States
GR  - P01 CA065493/CA/NCI NIH HHS/United States
GR  - P01 CA111412/CA/NCI NIH HHS/United States
GR  - UL1 TR000114/TR/NCATS NIH HHS/United States
GR  - KL2 TR000113/TR/NCATS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
PL  - United States
TA  - Crit Rev Oncog
JT  - Critical reviews in oncogenesis
JID - 8914610
SB  - IM
MH  - Humans
MH  - Killer Cells, Natural/*immunology
MH  - Neoplasms/*immunology
PMC - PMC4066212
MID - NIHMS590347
EDAT- 2014/06/19 06:00
MHDA- 2014/10/01 06:00
PMCR- 2015/01/01
CRDT- 2014/06/19 06:00
PHST- 2014/06/19 06:00 [entrez]
PHST- 2014/06/19 06:00 [pubmed]
PHST- 2014/10/01 06:00 [medline]
PHST- 2015/01/01 00:00 [pmc-release]
AID - 1495e1167ec31aaf,0bc693f71a4e0e95 [pii]
AID - 10.1615/critrevoncog.2014011091 [doi]
PST - ppublish
SO  - Crit Rev Oncog. 2014;19(1-2):133-41. doi: 10.1615/critrevoncog.2014011091.